Their topical and oral drugs target RORyt, providing safe and effective treatment options for both mild-to-moderate and moderate-to-severe psoriasis patients. The company's proprietary technology allows high penetration in dermal tissues, maximizing target engagement at the site of inflammation while minimizing off-target activity and immune suppression effects. Currently, Escalier's lead topical and oral drug candidates are in late stage preclinical studies.